Company profile
Adrenas Therapeutics company profile
Adrenas Therapeutics focuses on the development of gene therapies for the treatment of congenital adrenal hyperplasia (CAH), a monogenic disease that manifests in childhood. The company collaborates with scientists, physicians, and patients to advance its mission of creating effective gene therapy solutions. Adrenas Therapeutics is actively involved in clinical trials, including the ADventure investigational gene therapy clinical trial for adults with Classic CAH. Their research includes the use of Intravenous AAV5 Gene Therapy with Human CYP21A2, which has shown promising results in correcting phenotypic deficiencies in the 21-hydroxylase knockout mouse model.
Business identity
- Website
- https://adrenastx.com
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $0+
- Founded
- 2018-01-01
Headquarters
- Headquarters
- Creve Coeur, Missouri, United States
- Postal code
- 27607
- Country code
- US
- Continent
- North America